Tonight: Adia Nutrition and UCF CARD Host Live Zoom on Revolutionary Stem Cell Study for Autism - Strong Interest Already Building

Core Insights - Adia Nutrition Inc. is hosting a virtual presentation in collaboration with the Center for Autism and Related Disabilities (CARD) at UCF to discuss its clinical study on Autism Spectrum Disorder (ASD) [1][2][3] Group 1: Clinical Study and Presentation - The clinical study, identified as ClinicalTrials.gov ID: NCT07304440, is a 24-month trial recruiting children aged 3-12 with ASD, evaluating the efficacy of AdiaVita, which includes umbilical cord blood-derived stem cells and exosomes combined with glutathione [2][4] - The presentation aims to provide families, caregivers, and professionals with critical information about the study, emphasizing the safety and domestic nature of the trial [3][4] - Dr. Terri Daly from UCF CARD highlighted the strong community interest in the event, which offers parents a chance to learn about a U.S.-based study for potential enrollment [3][4] Group 2: Company Overview and Mission - Adia Nutrition Inc. specializes in regenerative medicine and offers products like AdiaVita and AdiaLink through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products [7][8] - The company operates Adia Med clinics that focus on orthopedic, pain management, and wound repair, providing advanced regenerative treatments such as stem cell therapies and platelet-rich plasma (PRP) [7][8] - Revenue is generated through service fees, product sales, equity stakes, and insurance billing for healthcare treatments, with a commitment to standardized, FDA-approved lab protocols [8]